Compare Stocks: IRD, RARE, ANAB, and KLRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$45.95 -0.6%	$54.41	$20.18 ▼ $72.36	$1.38B	0.76	588,049 shs	495,168 shs
IRD Opus Genetics	$4.65 +4.3%	$4.46	$1.70 ▼ $7.07	$368.61M	0.62	2.25 million shs	1.26 million shs
KLRA Kailera Therapeutics	$11.61 +16.1%	$15.03	$9.76 ▼ $28.23	$1.30B	N/A	1.45 million shs	2.18 million shs
RARE Ultragenyx Pharmaceutical	$15.48 +1.2%	$19.87	$12.73 ▼ $39.89	$1.51B	0.35	5.70 million shs	2.93 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-0.56%	-5.32%	-17.50%	-30.79%	+44.36%
IRD Opus Genetics	+4.26%	+1.53%	-18.85%	+18.62%	+126.83%
KLRA Kailera Therapeutics	+16.10%	+11.74%	-21.77%	-43.86%	+1,160,999,900.00%
RARE Ultragenyx Pharmaceutical	+1.24%	+1.71%	+8.18%	-54.23%	-49.84%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$45.95 -0.6%	$54.41	$20.18 ▼ $72.36	$1.38B	0.76	588,049 shs	495,168 shs
IRD Opus Genetics	$4.65 +4.3%	$4.46	$1.70 ▼ $7.07	$368.61M	0.62	2.25 million shs	1.26 million shs
KLRA Kailera Therapeutics	$11.61 +16.1%	$15.03	$9.76 ▼ $28.23	$1.30B	N/A	1.45 million shs	2.18 million shs
RARE Ultragenyx Pharmaceutical	$15.48 +1.2%	$19.87	$12.73 ▼ $39.89	$1.51B	0.35	5.70 million shs	2.93 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	-0.56%	-5.32%	-17.50%	-30.79%	+44.36%
IRD Opus Genetics	+4.26%	+1.53%	-18.85%	+18.62%	+126.83%
KLRA Kailera Therapeutics	+16.10%	+11.74%	-21.77%	-43.86%	+1,160,999,900.00%
RARE Ultragenyx Pharmaceutical	+1.24%	+1.71%	+8.18%	-54.23%	-49.84%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.71	Moderate Buy	$77.79	69.28% Upside
IRD Opus Genetics	2.89	Moderate Buy	$12.29	164.21% Upside
KLRA Kailera Therapeutics	2.75	Moderate Buy	$42.75	268.22% Upside
RARE Ultragenyx Pharmaceutical	2.48	Hold	$34.58	123.38% Upside

Current Analyst Ratings Breakdown

Latest IRD, RARE, ANAB, and KLRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/6/2026	KLRA Kailera Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (D-)
10/6/2026	RARE Ultragenyx Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/6/2026	IRD Opus Genetics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$10.00 ➝ $17.00
10/2/2026	IRD Opus Genetics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00
9/30/2026	ANAB AnaptysBio	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$70.00 ➝ $60.00
9/23/2026	ANAB AnaptysBio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$90.00 ➝ $81.00
9/23/2026	RARE Ultragenyx Pharmaceutical	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/22/2026	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$95.00
9/22/2026	ANAB AnaptysBio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/21/2026	RARE Ultragenyx Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$32.00 ➝ $35.00
9/18/2026	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$18.00 ➝ $20.00

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$234.60M	5.86	N/A	N/A	$1.34 per share	34.29
IRD Opus Genetics	$14.20M	27.06	N/A	N/A	$0.22 per share	21.14
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	$673M	2.27	N/A	N/A	($0.83) per share	-18.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$13.23M	$5.37	8.56	18.99	N/A	82.37%	112.00%	2.20%	11/3/2026 (Estimated)
IRD Opus Genetics	-$49.59M	-$1.35	N/A	N/A	N/A	-1,091.82%	N/A	-150.13%	11/11/2026 (Estimated)
KLRA Kailera Therapeutics	-$148.96M	-$3,651.09	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	N/A	-44.40%	11/3/2026 (Estimated)

Latest IRD, RARE, ANAB, and KLRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	ANAB AnaptysBio	-$1.84	N/A	N/A	N/A	$25.56 million	N/A
11/3/2026	Q3 2026	RARE Ultragenyx Pharmaceutical	-$0.9274	N/A	N/A	N/A	$182.62 million	N/A
9/21/2026	Q2 2026	ANAB AnaptysBio	-$0.4650	$5.11	+$5.5750	$5.11	$14.06 million	$27.49 million
8/12/2026	Q2 2026	KLRA Kailera Therapeutics	-$0.74	-$1.09	-$0.35	-$1.09	N/A	N/A
8/6/2026	Q2 2026	IRD Opus Genetics	-$0.1567	-$0.14	+$0.0167	-$0.14	$2.63 million	$0.76 million
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
KLRA Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	7.58	7.58
IRD Opus Genetics	N/A	12.19	12.19
KLRA Kailera Therapeutics	N/A	11.11	11.11
RARE Ultragenyx Pharmaceutical	N/A	1.73	1.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
IRD Opus Genetics	14.97%
KLRA Kailera Therapeutics	N/A
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	31.50%
IRD Opus Genetics	11.70%
KLRA Kailera Therapeutics	N/A
RARE Ultragenyx Pharmaceutical	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	104	29.90 million	20.48 million	Optionable
IRD Opus Genetics	28	82.65 million	72.98 million	N/A
KLRA Kailera Therapeutics	145	129.64 million	N/A	N/A
RARE Ultragenyx Pharmaceutical	1,371	98.59 million	93.46 million	Optionable

IRD, RARE, ANAB, and KLRA Headlines

Recent News About These Companies

Pharmaceutical Executive Daily: Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher

October 8 at 7:15 PM | pharmexec.comP

Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy?

October 8 at 7:15 PM | finance.yahoo.com

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

October 8 at 11:50 AM | zacks.com

Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

October 7 at 2:19 PM | marketscreener.comM

Ultragenyx To Sell Rare Pediatric Disease Voucher For $210 Mln

October 7 at 2:19 PM | rttnews.com

Ultragenyx lands $210M deal to sell FDA priority review voucher – Retail sees 'huge' buying opportunity

October 7 at 2:19 PM | msn.com

Ultragenyx to sell FDA priority review voucher for $210M

October 7 at 2:19 PM | seekingalpha.com

Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million

October 7 at 12:49 PM | proactiveinvestors.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Jumps 3.9% - Here's Why

October 7 at 12:19 PM | marketbeat.com

Ultragenyx Monetizes FDA Priority Review Voucher Asset

October 7 at 9:50 AM | tipranks.com

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

October 7 at 8:30 AM | globenewswire.com

Ultragenyx (RARE) EMA Validation of MPS IIIA Gene Therapy: Inflection Point or Incremental Milestone?

October 7 at 1:06 AM | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

October 6, 2026 | globenewswire.com

Comparing Ultragenyx Pharmaceutical (NASDAQ:RARE) & Mereo BioPharma Group (NASDAQ:MREO)

October 6, 2026 | americanbankingnews.com

Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

October 5, 2026 | zacks.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Down 6% - Should You Sell?

October 5, 2026 | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 6% - Here's Why

October 5, 2026 | marketbeat.com

Gene therapy for rare lysosomal storage disorder nabs FDA approval

October 5, 2026 | nature.comN

Ultragenyx Pharmaceutical | Science & Technology

October 3, 2026 | note.comN

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA ...

October 2, 2026 | finance.yahoo.com

Ultragenyx's MPS IIIA Gene Therapy Application Validated By EMA

October 2, 2026 | rttnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IRD, RARE, ANAB, and KLRA Company Descriptions

AnaptysBio NASDAQ:ANAB

$45.95 -0.26 (-0.56%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$45.88 -0.07 (-0.15%)

As of 10/9/2026 07:44 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Opus Genetics NASDAQ:IRD

$4.65 +0.19 (+4.26%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.68 +0.03 (+0.67%)

As of 10/9/2026 07:49 PM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

Kailera Therapeutics NASDAQ:KLRA

$11.61 +1.61 (+16.10%)

As of 10/9/2026 04:00 PM Eastern

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. With our obesity-first focus, we have built a diversified pipeline of product candidates specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate that we believe offers the potential for the greatest weight loss. We are rapidly progressing four clinical-stage product candidates, leveraging multiple glucagon-like peptide-1, or GLP-1, based mechanisms of action and routes of administration. Our lead product candidate, ribupatide (also known as KAI-9531), is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide, or GIP, receptor dual agonist peptide that we believe offers the potential for the greatest weight loss compared to all obesity management medications currently marketed or in development with a tolerability profile that is class-like or better. We are expanding our ribupatide franchise by developing a once-daily oral tablet formulation, oral ribupatide, based on the same peptide as injectable ribupatide, to provide a convenient oral option with the potential for highly differentiated tolerability with compelling weight loss among oral treatments. Additionally, we are advancing a second oral product candidate, KAI-7535, a once-daily small molecule GLP-1 receptor agonist with the potential to improve on the clinical profile of existing oral treatments. Finally, we are developing KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist, that leverages an incremental mechanism to potentially deliver compelling weight loss, improved liver fat reduction and a differentiated tolerability profile. KAI-4729 is based on a different peptide than injectable ribupatide and oral ribupatide. Obesity is a chronic, complex disease characterized by the accumulation of excessive body fat, resulting in significant negative impacts on health and quality of life. The most severely impacted patient population, people with a body mass index, or BMI, of 35 kg/m2 or greater, which we refer to as a BMI of 35+, represents the fastest growing and largest segment of this population, with half of U.S. adults with obesity expected to have a BMI of 35+ by 2030. While the approvals of GLP-1-based obesity management medications have changed the landscape of obesity management, there remains a critical need for medications offering greater weight loss, especially for those living with a higher BMI. For example, in the SURMOUNT-1 Phase 3 clinical trial, the majority of patients who had a baseline BMI of 35+ and were treated with tirzepatide, the most prescribed weight loss medicine today, were still living with obesity at the end of treatment. Both physicians and patients have identified expected weight loss as a primary treatment goal, with the magnitude of weight reduction serving as a crucial driver in therapy selection. We believe that injectable treatments will remain foundational for patients needing significant weight reduction. Meanwhile, for patients with a lower BMI, lower incidences of gastrointestinal side effects may be needed to achieve optimal weight loss and treatment persistence, and we believe oral treatments can unlock adoption for those with more modest weight loss needs, while also supporting the chronic treatment journey of those living with higher BMIs. We were originally incorporated under the laws of the State of Delaware on May 8, 2024 under the name Hercules CM Newco, Inc. We changed our name to Kailera Therapeutics, Inc. on August 22, 2024. Our principal executive offices are located in Waltham, Massachusetts.

Ultragenyx Pharmaceutical NASDAQ:RARE

$15.48 +0.19 (+1.24%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$15.59 +0.11 (+0.72%)

As of 10/9/2026 07:56 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRD, RARE, ANAB, and KLRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRD, RARE, ANAB, and KLRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRD, RARE, ANAB, and KLRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRD, RARE, ANAB, and KLRA Company Descriptions

AnaptysBio NASDAQ:ANAB

Opus Genetics NASDAQ:IRD

Kailera Therapeutics NASDAQ:KLRA

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRD, RARE, ANAB, and KLRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRD, RARE, ANAB, and KLRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRD, RARE, ANAB, and KLRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRD, RARE, ANAB, and KLRA Company Descriptions

AnaptysBio NASDAQ:ANAB

Opus Genetics NASDAQ:IRD

Kailera Therapeutics NASDAQ:KLRA

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools